A5080093777- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Drug-Induced Adverse Reactions
- Nonmelanoma Skin Cancer Studies
- Chemotherapy-related skin toxicity
- Cell Image Analysis Techniques
- Cutaneous lymphoproliferative disorders research
- Chronic Lymphocytic Leukemia Research
- Dermatological and Skeletal Disorders
- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Dermatologic Treatments and Research
- Optical Coherence Tomography Applications
- AI in cancer detection
- Cancer and Skin Lesions
- Biosimilars and Bioanalytical Methods
- melanin and skin pigmentation
- Acne and Rosacea Treatments and Effects
- Genetic and rare skin diseases.
- Diagnosis and Treatment of Venous Diseases
Massachusetts General Hospital
2022-2025
Brigham and Women's Hospital
2023-2024
Dana-Farber Cancer Institute
2022-2024
Harvard University
2022-2023
The University of Texas Southwestern Medical Center
2021-2023
Southwestern Medical Center
2022
Mass General Brigham
2022
The University of Texas at Austin
2013
Rockefeller University
1995
Prognostic analysis for early-stage (stage I/II) melanomas is of paramount importance customized surveillance and treatment plans. Since immune checkpoint inhibitors have recently been approved stage IIB IIC melanomas, prognostic tools to identify patients at high risk recurrence become even more critical. This study aims assess the effectiveness machine-learning algorithms in predicting melanoma using clinical histopathologic features from Electronic Health Records (EHRs). We collected 1720...
Abstract Background Cutaneous immune-related adverse events (cirAEs) are the most common toxicities to occur in setting of immune checkpoint inhibitor (ICI) therapy. Identifying patients who at increased risk developing cirAEs may improve quality life and outcomes. Objectives To investigate influence cancer type histology on development ICI therapy survival Methods This retrospective cohort study included recruited between 1 December 2011 30 October 2020. They received from 2020 with...
Dupilumab has been added to National Cancer Comprehensive Network (NCCN) guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitor (ICI) therapy. However, little is known about the implications of dupilumab cancer outcomes in this population. In multi-institutional study, we evaluate impact treatment on survival among ICI recipients. We conducted muti-institutional retrospective cohort study recipients Mass...
Although indications for immune checkpoint inhibitors (ICIs) have dramatically increased in the past decade, ICIs been associated with autoinflammatory immune-related adverse events, which can resemble autoimmune diseases (ADs). Little is known about impact of baseline AD on mortality cancer patients treated ICIs. Here, we identified 17 497 preexisting diagnoses prior to treatment antiprogrammed cell death receptor-1 or ligand-1 therapy and matched controls through TriNetX Diamond network...
Cutaneous immune-related adverse events (irAEs) are the most common irAEs caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both de novo and flares, may occur. Evidence is lacking on inverse psoriasis subtype.A retrospective study was conducted at Dana-Farber Cancer Institute/Mass General Brigham through February 2020 using databases. Confirmed cases pre-/post-ICI initiation either independently or in conjunction with other subtypes were included. Known without flare...
Immune checkpoint inhibition (ICI) can induce progression of pre-existing radiation-induced morphoea beyond the irradiated field and into deeper structures including muscle fascia. Dupilumab, an interleukin-4 receptor antagonist, should be considered in patients with refractory radiation or ICI-induced may allow for continued anticancer treatment.
Click to increase image sizeClick decrease size Author contributionsAll authors made substantial contributions conception and design, acquisition of data, or analysis interpretation data. All were involved in drafting the article revising it critically for important intellectual content. provided final approval manuscript agree be accountable all aspects work.Disclosure statementNicole R. LeBoeuf is a consultant has received honoraria from Bayer, Seattle Genetics, Sanofi, Silverback Synox...
Relationships between pre-existing inflammatory diseases (pIDs) and cutaneous immune-related adverse events (cirAEs) have not been well-studied. This study is to investigate associations pIDs cirAEs among immune-checkpoint inhibitor (ICI) recipients at the Mass General Brigham healthcare system.Electronic health records were reviewed ascertain cirAE status. Patients' pID status was determined using International Classification of Diseases (ICD) codes. Cox proportional hazard, logistic...
Abstract: Podophyllotoxin (PPT) is used to treat condylomata acuminata and works by destabilizing microtubules within epithelial cells, leading mitotic arrest in metaphase. PPT-induced changes the epidermis can cause histological findings mimicking dysplasia. Here, we present a case of vulvar condyloma acuminatum treated with PPT, showing ballooning degeneration, necrotic keratinocytes, figures. PPT-treated skin may resemble dysplasia or squamous cell carcinoma situ due dyskeratosis frequent...